Alvimopan

Alvimopan (ADL 8-2698) is a potent, selective, orally active and reversible μ-opioid receptor antagonist, with an IC50 of 1.7 nM. Alvimopan has selectivity for μ-opioid receptor (Ki=0.47 nM) over κ- and δ-opioid receptors (Kis=100, 12 nM, respectively) . Alvimopan can be used for the research of postoperative ileus[1][2][3].

Product Specifications

CAS Number

[156053-89-3]

Product Name Alternative

ADL 8-2698; LY 246736

UNSPSC

12352005

Hazard Statement

H315, H319, H400

Target

Opioid Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Neurological Disease; Cancer

Assay Protocol

https://www.medchemexpress.com/alvimopan.html

Purity

98.66

Solubility

DMSO : ≥ 100 mg/mL

Smiles

O=C(CNC([C@@H](CC1=CC=CC=C1)CN2C[C@@H]([C@](C3=CC=CC(O)=C3)(CC2)C)C)=O)O

Molecular Formula

C25H32N2O4

Molecular Weight

424.53

Precautions

H315, H319, H400

References & Citations

[1]Bourdonnec BL, et, al. Novel trans-3,4-dimethyl-4- (3-hydroxyphenyl) piperidines as mu opioid receptor antagonists with improved opioid receptor selectivity profiles. Bioorg Med Chem Lett. 2008 Mar 15;18 (6) :2006-12.|[2]Erowele GI, et, al. Alvimopan (Entereg), a Peripherally Acting mu-Opioid Receptor Antagonist For Postoperative Ileus. P T. 2008 Oct;33 (10) :574-83.|[3]Meerveld BG, et, al. Preclinical studies of opioids and opioid antagonists on gastrointestinal function. Neurogastroenterol Motil. 2004 Oct;16 Suppl 2:46-53.